183 related articles for article (PubMed ID: 16087902)
1. Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease.
Popat RA; Van Den Eeden SK; Tanner CM; McGuire V; Bernstein AL; Bloch DA; Leimpeter A; Nelson LM
Neurology; 2005 Aug; 65(3):383-90. PubMed ID: 16087902
[TBL] [Abstract][Full Text] [Related]
2. Effect of reproductive factors and postmenopausal hormone use on the risk of amyotrophic lateral sclerosis.
Popat RA; Van Den Eeden SK; Tanner CM; Bernstein AL; Bloch DA; Leimpeter A; McGuire V; Nelson LM
Neuroepidemiology; 2006; 27(3):117-21. PubMed ID: 16946622
[TBL] [Abstract][Full Text] [Related]
3. Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study.
Benedetti MD; Maraganore DM; Bower JH; McDonnell SK; Peterson BJ; Ahlskog JE; Schaid DJ; Rocca WA
Mov Disord; 2001 Sep; 16(5):830-7. PubMed ID: 11746612
[TBL] [Abstract][Full Text] [Related]
4. Risk of Parkinson disease in women: effect of reproductive characteristics.
Ragonese P; D'Amelio M; Salemi G; Aridon P; Gammino M; Epifanio A; Morgante L; Savettieri G
Neurology; 2004 Jun; 62(11):2010-4. PubMed ID: 15184606
[TBL] [Abstract][Full Text] [Related]
5. Lifetime exposure to estrogens and Parkinson's disease in California teachers.
Gatto NM; Deapen D; Stoyanoff S; Pinder R; Narayan S; Bordelon Y; Ritz B
Parkinsonism Relat Disord; 2014 Nov; 20(11):1149-56. PubMed ID: 25179495
[TBL] [Abstract][Full Text] [Related]
6. Postmenopausal estrogen use affects risk for Parkinson disease.
Currie LJ; Harrison MB; Trugman JM; Bennett JP; Wooten GF
Arch Neurol; 2004 Jun; 61(6):886-8. PubMed ID: 15210525
[TBL] [Abstract][Full Text] [Related]
7. Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study.
DeBono NL; Robinson WR; Lund JL; Tse CK; Moorman PG; Olshan AF; Troester MA
J Womens Health (Larchmt); 2018 Mar; 27(3):377-386. PubMed ID: 28570827
[TBL] [Abstract][Full Text] [Related]
8. Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials.
Maalouf NM; Sato AH; Welch BJ; Howard BV; Cochrane BB; Sakhaee K; Robbins JA
Arch Intern Med; 2010 Oct; 170(18):1678-85. PubMed ID: 20937929
[TBL] [Abstract][Full Text] [Related]
9. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: US Preventive Services Task Force Recommendation Statement.
; Grossman DC; Curry SJ; Owens DK; Barry MJ; Davidson KW; Doubeni CA; Epling JW; Kemper AR; Krist AH; Kurth AE; Landefeld CS; Mangione CM; Phipps MG; Silverstein M; Simon MA; Tseng CW
JAMA; 2017 Dec; 318(22):2224-2233. PubMed ID: 29234814
[TBL] [Abstract][Full Text] [Related]
10. Association Between Menopausal Hormone Therapy and Risk for Parkinson's Disease.
Yuk JS; Jeong SH
J Parkinsons Dis; 2023; 13(8):1357-1367. PubMed ID: 37980684
[TBL] [Abstract][Full Text] [Related]
11. Postmenopausal hormone therapy and risk of stroke: A pooled analysis of data from population-based cohort studies.
Carrasquilla GD; Frumento P; Berglund A; Borgfeldt C; Bottai M; Chiavenna C; Eliasson M; Engström G; Hallmans G; Jansson JH; Magnusson PK; Nilsson PM; Pedersen NL; Wolk A; Leander K
PLoS Med; 2017 Nov; 14(11):e1002445. PubMed ID: 29149179
[TBL] [Abstract][Full Text] [Related]
12. Prior hysterectomy and oophorectomy and incident venous thrombosis risk among postmenopausal women: a population-based, case-control study.
Harrington LB; Weiss NS; Wiggins KL; Heckbert SR; McKnight B; Blondon M; Woods NF; LaCroix AZ; Psaty BM; Smith NL
Menopause; 2016 Feb; 23(2):143-9. PubMed ID: 26757272
[TBL] [Abstract][Full Text] [Related]
13. Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease.
Simon KC; Chen H; Gao X; Schwarzschild MA; Ascherio A
Mov Disord; 2009 Jul; 24(9):1359-65. PubMed ID: 19424986
[TBL] [Abstract][Full Text] [Related]
14. Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: the Women's Health Initiative Hormone Therapy clinical trials.
Canonico M; Plu-Bureau G; O'Sullivan MJ; Stefanick ML; Cochrane B; Scarabin PY; Manson JE
Menopause; 2014 Mar; 21(3):214-20. PubMed ID: 23760439
[TBL] [Abstract][Full Text] [Related]
15. Reproductive and menstrual risk factors for pancreatic cancer: a population-based study of San Francisco Bay Area women.
Duell EJ; Holly EA
Am J Epidemiol; 2005 Apr; 161(8):741-7. PubMed ID: 15800266
[TBL] [Abstract][Full Text] [Related]
16. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.
Schairer C; Lubin J; Troisi R; Sturgeon S; Brinton L; Hoover R
JAMA; 2000 Jan; 283(4):485-91. PubMed ID: 10659874
[TBL] [Abstract][Full Text] [Related]
17. Options for hormone therapy in women who have had a hysterectomy.
Haney AF; Wild RA
Menopause; 2007; 14(3 Pt 2):592-7; quiz 598-9. PubMed ID: 17476150
[TBL] [Abstract][Full Text] [Related]
18. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
JAMA; 1996 Feb; 275(5):370-5. PubMed ID: 8569016
[TBL] [Abstract][Full Text] [Related]
19. Hysterectomy, bilateral oophorectomy, and breast cancer risk in a racially diverse prospective cohort study.
Lovett SM; Sandler DP; O'Brien KM
J Natl Cancer Inst; 2023 Jun; 115(6):662-670. PubMed ID: 36806439
[TBL] [Abstract][Full Text] [Related]
20. The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review.
Oliver-Williams C; Glisic M; Shahzad S; Brown E; Pellegrino Baena C; Chadni M; Chowdhury R; Franco OH; Muka T
Hum Reprod Update; 2019 Mar; 25(2):257-271. PubMed ID: 30508190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
